The latest articles, press releases and dossiers on pharmaceutics in Baden-Württemberg
Article - 17-Oct-2018
Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.
Article - 02-Oct-2018
Artificial intelligence is currently one of the most innovative issues, but also one of the most controversial research areas. It already has a firm footing in many areas of our everyday life and often we are not even aware of it. Artificial intelligence has long been an integral part of many processes in research and diagnostics in medicine and the life sciences – and it will be even more widely used in the future.
Press release - 27-Sep-2018
BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English. The topic neatly dovetails with the state’s political activities. An evaluation of the region carried out on behalf of the Baden-Württemberg government has clearly recognised the importance of the healthcare sector as a driver of innovation.
Article - 31-Jul-2018
Deafness is one of the most common sensory disorders in the world: in Germany alone, around eleven million people suffer from hearing loss. So far there is no real therapy, the symptoms can only be alleviated to a greater or lesser degree. This is what researchers from the Tübingen-based company Acousia Therapeutics want to change: they have identified drug candidates that can protect sensory hair cells and support their function.
Article - 23-May-2018
Multidrug-resistant bacteria are resistant to many existing antibiotics and can be difficult to treat. There are increasing numbers of them worldwide. Although novel antibiotics are being developed, there are far too few of them to tackle the rise of multidrug-resistant bacteria. In Eastern Europe, doctors have been treating bacterial infections with viruses that infect bacteria, so-called bacteriophages, for almost 100 years.
Article - 05-Apr-2018
It can take many decades before promising research results become therapies that have a positive effect on cancer patients. Most research projects go adrift somewhere between the laboratory and the bedside in the so-called "valley of death". Projects carried out at the DKFZ show that translational cancer research actually works.
Article - 21-Mar-2018
At present, potential new drugs have to be tested on animals before they can be used on humans. However, results obtained from animals are not always transferrable to the situation in humans, which is why researchers around the world have long been seeking alternatives. Miniature human organs that can be used to test the efficacy of potential human drugs might provide a solution.
Article - 21-Feb-2018
HepaRegeniX, a biotech company founded in 2016, specialises in developing drugs that restore the regenerative capacity of diseased livers. The three founders of the biotech start-up, Prof. Dr. Lars Zender, Prof. Dr. Stefan Laufer and Dr. Wolfgang Albrecht, anticipate starting clinical testing of the first drug candidate in 2019.
Article - 14-Feb-2018
Quite a number of promising drug candidates for the treatment of diabetes are currently in the pharmaceutical pipeline, including innovative drugs that can stimulate the regeneration of insulin-producing pancreatic cells. However, they will have to be safety tested in animals. Scientists from Ulm University Hospital have now begun to develop a pancreatic chip from stem cells.
Press release - 13-Feb-2018
Extends ongoing collaboration with Bill & Melinda Gates Foundation with award of two new grants. CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the awarding of two new grants from the Bill & Melinda Gates Foundation.
Article - 07-Dec-2017
“Stop experimenting – GoSilico” is the motto of a young start-up company from Karlsruhe. The founding team of GoSilico GmbH is causing a furore with a simulation software that would make many laboratory experiments obsolete. The chromatographic separation of biomolecules from organisms, samples and cell cultures can be reliably simulated after just a few starter experiments. This saves time, work, material and costs in pharmaceutical development.
Article - 06-Nov-2017
Peptide- and protein-based drugs like those used for treating diabetes, cancer and autoimmune diseases cannot be administered orally. This is because these biomolecules degrade in the gastrointestinal tract, thus preventing them from reaching their target site in the body. Protein- and peptide-base drugs therefore have to be administered by way of injection, which is comparatively complicated and painful. However, a start-up company called Heidelberg Delivery Technologies GmbH has now developed an innovative technology that makes taking medicines as easy as eating gummy bears.